title: An experimental evaluation of the euphoric properties of antiparkinson drugs on psychotic patients.
abstract: Seven psychotic inpatients (two women and five men) aged between 18 and 74 years, treated with neuroleptic and antiparkinson drugs, participated in a double-blind study with 1/3 DDD (Defined Daily Dose) of procyclidine, orphenadrine, or trihexyphenidyl hydrochloride against placebo. Euphoric effects were scored on a self-rating scale and extrapyramidal side-effects on the Simpson-Angus rating scale at drug administration and 1, 3 and 6 h thereafter. With regard to euphoric effect, there was a significant (P less than 0.02) difference between start and end point (0 and 6 h) for placebo but not for the active antiparkinson drugs. There was no significant difference in extrapyramidal side-effects. No preference of drug was found, and it was not possible to recognize the patient's own drug among the tested drugs. Side-effects from the antiparkinson drugs were also measured prior to the administration. Five patients did not return to their earlier antiparkinson drugs after the study.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects; D004311:Double-Blind Method; D005059:Euphoria; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009966:Orphenadrine / Q000009:adverse effects / Q000494:pharmacology*; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*; D011352:Procyclidine / Q000009:adverse effects / Q000494:pharmacology*; D011618:Psychotic Disorders / Q000188:drug therapy*; D011759:Pyrrolidines / Q000494:pharmacology*; D014282:Trihexyphenidyl / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D014150:Antipsychotic Agents; D011759:Pyrrolidines; D014282:Trihexyphenidyl; D009966:Orphenadrine; D011352:Procyclidine